Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

European Health Summit 2022

Vivactis Market Access attended the European Health Summit on December 8th

The European Health Summit is an annual event organised by the European Business Summits.  The focus is on bringing together businesses, policymakers, and academia to debate the key healthcare issues in Europe and beyond.

We joined to get the latest insights from international experts.

Interesting discussion panels, such as:

Showcasing the power of cross industry collaboration for digital acceleration, innovation and global health“. 
As EU institutions discuss new pieces of legislation (such as the EHDS) and ways to enhance coordination on global health topics, this panel session highlighted the value of cross-industry collaboration and shed a light on technology innovation within healthcare. 

Towards a rare disease moonshot: scaling up public and private partnerships to accelerate research“.

95% of the 6,000-7,000 identified rare diseases don’t have an approved therapy. For most of these diseases, research is effectively non-existent. The search for new treatments is thwarted by enormous scientific challenges. At the current pace, it would take over 100 years to develop treatments for all rare conditions.

Public-private partnerships could help pool resources to solve problems more quickly, reduce fragmentation and scale up existing initiatives to make a real difference for patients. That’s why a coalition of partners is joining forces to accelerate research in rare and paediatric diseases and bring new therapies to patients.

More information: https://www.europeanhealthsummit.eu/ehs-2022-programme/